Symkevi Approved in EU for CF Patients with Two F508del Mutations, or One Plus a Minimal Function Mutation
cystic fibrosis, News
Symkevi (tezacaftor/ivacaftor combo), by Vertex Pharmaceuticals, has been approved in the European Union for patients with cystic fibrosis (CF) ages 12 or older who carry F508del mutations. Importantly, the European Commission’s decision to grant marketing ... Read more